thought organ trend guid
focu organ growth investor focu today center
underli organ trend within guidanc includ follow
compon share repurchas contribut ep growth total
ep increas wage addl invest mln creat
drag ep growth tax rate core busi growth gross
margin expect see distinct increas expect
margin contributor due higher interest expens regard expect
improv gross margin indic driven part
lap fep contract also see benefit fred
davita rx file buy despit headwind continu reimburs pressur
indic good visibl gross margin year see
benefit focu front-end margin store optim plan expect
complet end addit compani increas synergi
expect optim program mln mln altogeth
guidanc impli ebit growth management believ quit good given
current headwind howev depend view contribut within
investor still seemingli perceiv organ ebit growth neg
rais ep modestli rais ep estim slightli account
slightli higher share buyback slightli lower tax partial off-set lower ebit
growth ep view
new pt base price-to-earnings slightli higher ep
regard compani partnership provid
financi detail except mention rent labcorp off-set near-term
dilut cost accret out-year management also reinforc
would pursu larger expand deal lh benefit
final management also rule possibl larger rx deal kr road
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight walgreen continu forg
ahead integr asset
move cost cut mode may yield
synergi larg price point
upsid case see modest margin
expans ep growth capit alloc
usag benefit partnership
addit greater expect cost cut
downsid case compani make
action beyond current strategi complet
acquisit reduc store count
reimburs pressur like persist
lead multipl contract
recal compani initi store optim plan compani expect
close store period compani alreadi complet store
closur in-lin plan expect complet optim
program end total benefit store optim synergi
program expect mln year compar origin mln year
cost program remain bln regard store
acquir management indic strong execut lead favor prescript volum
retent management indic retent rate higher seen
histor regard quarter soft gross margin quarter
manag note driven part specialti also contract payment
time neg impact margin bp quarter
regard compani quarterli trend compani indic like
similar trend distinct gross margin
improv sg rate within retail us busi management
expect sg repeat move forward one-tim item
benefit compani quarter management expect uptick sg rate
move regard compani lever move forward management expect
on-going reimburs pressur off-set volum acquir
rad/freds/davitarx management note procur gener signific
driver benefit prior year benefit tail littl bit compens
management push lower sg time
 tax bln worth share mln ep growth reposexclud anti-dilutivecor busi grow contribut barclay
 quarterli retail drugstor data pharmacyactualactualactualactualprojectedprojectedprojectedprojectedu drugstor datastor beg number number per chang yr/yrtot per dataprescript sale usa per scriptrev per prescript rx chang yr/yrpharmaci rx store sale data pharmaci front-end drugstor barclay
 quarterli segment analysi revenueactualactualactualactualprojectedprojectedprojectedprojectedretail pharmaci pharmaci chang yr/yrretail pharmaci pharmaci segment gross profitretail pharmaci pharmaci gross profit marginretail pharmaci pharmaci gross profit chang yr/yrretail pharmaci pharmaci -- -- -- -- -- -- -- -- total gross profit sg aretail pharmaci pharmaci revenueretail pharmaci pharmaci chang yr/yrretail pharmaci pharmaci -- -- -- -- -- -- -- -- total sg segment ebitretail pharmaci pharmaci adjust marginretail pharmaci pharmaci ebit chang yr/yrretail pharmaci pharmaci -- -- -- -- -- -- -- -- total ebit barclay
 quarterli incom statement addback invest affili incom revenu excl expens net rate non-controlling interest swiss net check ep fulli dilut share growth comparisontot incom expens net net per barclay
 annual retail drugstor data pharmacyactualactualprojectedprojectedprojectedprojectedu drugstor datastor beg number number per chang yr/yrtot per dataprescript sale usa per scriptrev per prescript rx chang yr/yrpharmaci rx store sale data pharmaci front-end drugstor barclay
 annual segment analysi revenueactualactualprojectedprojectedprojectedprojectedretail pharmaci pharmaci chang yr/yrretail pharmaci pharmaci segment gross profitretail pharmaci pharmaci gross profit marginretail pharmaci pharmaci gross profit chang yr/yrretail pharmaci pharmaci -- -- -- -- -- -- total gross profit sg aretail pharmaci pharmaci revenueretail pharmaci pharmaci chang yr/yrretail pharmaci pharmaci -- -- -- -- -- -- total sg segment ebitretail pharmaci pharmaci adjust marginretail pharmaci pharmaci -- -- -- -- -- -- total ebit chang yr/yrretail pharmaci pharmaci -- -- -- -- -- -- total ebit barclay
 annual incom statement addback invest affili incom revenu excl expens net rate non-controlling interest swiss net check ep fulli dilut share growth comparisontot incom expens net net per barclay
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
